Bio-Rad Laboratories (NYSE:BIO) this week touted a joint legal victory with the University of Chicago in a US Federal District court against rival 10X Genomics, saying that it was awarded $23.9 million in damages in a patent infringement case.
The jury in the trial unanimously found that 10X Genomics willfully infringed on Bio-Rad and Univ. of Chicago patents with its Single Cell and Linked-Read genomics products, the Hercules, Calif.-based company said.
“We are obviously pleased with the outcome of the case. Bio-Rad remains committed to growing and protecting its portfolio of patents in the droplet microfluidics space and to delivering differentiated genomics technologies that enable world class research,” prez & CEO Norman Schwartz said in a press release.
Bio-Rad said that in a separate earlier action before the International Trade Commission, an administrative law judge made an initial determination that certain microfluidic devices used by 10X in its products also infringe on rights owned by BioRad.
Last February, Bio-Rad agreed to pay $3.5 million in legal fees for the team that represented former general counsel, Sanford Wadler, during a whistleblower retaliation lawsuit Wadler brought against his former employer.